Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Functional reconstitution of the MERS CoV receptor binding motif

Lakshminarasaih Uppalapati, Anna Roitburd-Berman, Yael Weiss-Ottolenghi, Barney S. Graham, Dimiter S. Dimitrov, Tianlei Ying, Hila Failayev, Yossi Tsfadia, Jonathan M. Gershoni

Abstract

In the early 1960s the first human coronaviruses (designated 229E and OC43) were identified as etiologic agents of the common cold, to be followed by the subsequent isolation of three more human coronaviruses similarly associated with cold-like diseases. In contrast to these “mild” coronaviruses, over the last 20 years there have been three independent events of emergence of pandemic severe and acute life-threatening respiratory diseases caused by three novel beta-coronaviruses, SARS CoV, MERS CoV and most recently SARS CoV2. Whereas the first SARS CoV appeared in November 2002 and spontaneously disappeared by the summer of 2003, MERS CoV has continued persistently to spill over to humans via an intermediary camel vector, causing tens of cases annually. Although human-to-human transmission is rare, the fatality rate of MERS CoV disease is remarkably higher than 30%. COVID-19 however, is fortunately much less fatal, despite that its etiologic agent, SARS CoV2, is tremendously infectious, particularly with the recent evolution of the Omicron variants of concern (BA.1 and BA.2). Of note, MERS CoV prevalence in camel populations in Africa and the Middle East is extremely high. Moreover, MERS CoV and SARS CoV2 co-exist in the Middle East and especially in Saudi Arabia and the UAE, where sporadic incidences of co-infection have already been reported. Co-infection, either due to reverse spill-over of SARS CoV2 to camels or in double infected humans could lead to recombination between the two viruses, rendering either SARS CoV2 more lethal or MERS CoV more transmittable. In an attempt to prepare for what could develop into a catastrophic event, we have focused on developing a novel epitope-based immunogen for MERS CoV. Implementing combinatorial phage-display conformer libraries, the Receptor Binding Motif (RBM) of the MERS CoV Spike protein has been successfully reconstituted and shown to be recognized by a panel of seven neutralizing monoclonal antibodies.

1. Introduction

On November 16, 2002, a 64-year-old man from the Guangdong province in China died from an unknown respiratory disease (Peiris et al., 2004; Rota et al., 2003). In the fullness of time he would be known as “Patient Zero” of what would be the first of three beta-coronavirus outbreaks in the last 20 years. Severe Acute Respiratory Syndrome (SARS) is caused by what had been a previously unknown coronavirus (SARS CoV) (Rota et al., 2003). The natural reservoir of the virus is bats (Hu et al., 2017); however, an intermediate vector, masked civets, was initially identified (Wang et al., 2006). These predators populated the food markets frequently and so in an effort to curb the spread of the...
A second coronavirus outbreak occurred in 2012, in the Saudi peninsula leading to Middle East Respiratory Syndrome (MERS) which is caused by MERS CoV (Al-Abdallat et al., 2014; Killerby et al., 2020; Zaki et al., 2006). Since 2004 (Low, 2004; Stockman et al., 2012), similar to the SARS epidemic, MERS CoV apparently transfer from bats to an intermediate vector, this time dromedary camels, and from camels spill-over to humans (Durai et al., 2015). The latest update from the European Centre for Disease Prevention and Control (ECDC) on the MERS CoV threat (31 December, 2021) is that a total of 2600 cases in 27 countries have been reported with 943 deaths (fatality rate of 36%) (ECDC, 2022). Since the emergence of MERS CoV, every year there have been multiple cases and deaths reported, mainly from the Saudi Peninsula, Table 1 (FAO, 2022; Robert Carlson, 2021). Of note was an isolated, but serious, focused outbreak that occurred in 2015 in South Korea where 185 cases (and one more in China) were detected leading to 38 deaths (WHO, 2021). In response, over 16,900 cats, tigers, minks and ferrets (Banerjee et al., 2021; Hobbs and Reid, 2021) were destroyed in a massive culling action to contain the virus and prevent spread.

Table 1
MERS CoV cases in humans by country and dates. Data were obtained from Ministries of Agriculture or Livestock, Ministry of Health; Centers for Disease Prevention and Control (CDC) and World Health Organization (WHO), World Organization for Animal Health (OIE).

| Date of first case | Country | MERS-CoV infections in human | Last Observation | Covid-19 on 5/02/22 |
|-------------------|---------|-----------------------------|-----------------|-------------------|
| 13/06/2012        | Saudi Arabia | 2184 | 29/12/2021 | 708,650 |
| 19/03/2013        | United Arab Emirates | 93 | 06/11/2021 | 857,633 |
| 02/04/2012        | Jordan | 28 | 26/09/2015 | 1326,993 |
| 15/06/2013        | Qatar | 23 | 18/02/2020 | 349,027 |
| 26/10/2013        | Oman | 24 | 20/02/2019 | 351,641 |
| 11/05/2014        | Iran (Islamic Republic of) | 6 | 18/03/2015 | 6566,967 |
| 30/10/2013        | Kuwait | 4 | 08/09/2015 | 579,032 |
| 22/04/2014        | Lebanon | 2 | 08/06/2017 | 974,099 |
| 17/03/2014        | Yemen | 1 | 11/167 |
| 04/04/2016        | Bahrain (the Kingdom of) | 1 | 420,806 |
| 11/05/2015        | Republic of Korea | 185 | 28/08/2018 | 1007,380 |
| 15/04/2014        | Philippines | 2 | 30/06/2015 | 3608,632 |
| 10/06/2015        | Thailand | 3 | 25/07/2016 | 2496,612 |
| 21/05/2015        | China | 1 | 21/05/2015 | 106,324 |
| 08/04/2014        | Malaysia | 2 | 24/12/2017 | 2913,248 |
| 03/09/2012        | United Kingdom | 5 | 16/08/2018 | 17,810,577 |
| 05/10/2012        | Germany | 3 | 07/03/2015 | 11,112,069 |
| 01/05/2014        | Netherlands | 2 | 05/05/2014 | 4837,279 |
| 23/04/2013        | France | 2 | 27/04/2013 | 20,735,309 |
| 22/09/2014        | Austria | 2 | 08/09/2016 | 2059,862 |
| 25/09/2014        | Turkey | 1 | 25/09/2014 | 12,249,282 |
| 25/05/2013        | Italy | 1 | 25/05/2013 | 11,635,950 |
| 08/04/2014        | Greece | 1 | 08/04/2014 | 2052,892 |
| 14/04/2014        | United States of America | 2 | 01/05/2014 | 78,071,713 |
| 01/05/2013        | Tunisia | 3 | 17/06/2013 | 945,734 |
| 23/05/2014        | Algeria | 2 | 23/05/2014 | 258,390 |
| 22/04/2014        | Egypt | 1 | 2493,648 |

In total contrast to MERS CoV, in December 2019 a third pandemic event emerged in Wuhan, China with the appearance of a new beta-coronavirus, SARS CoV2 (Zhou et al., 2020). Since the emergence of MERS CoV, every year there have been multiple cases and deaths reported, mainly from the Saudi Peninsula, particularly in the hospital - patient setting. Thus, the overall pandemic reflects more multiple zoonotic spill-over events, rather than human-to-human transmission (Berruga-Fernandez et al., 2021; A.-R. Zhang et al., 2021). Fortunately, the virus seems not to have adapted for efficient human transmission.

1 In a retrospective study, an earlier case of MERS was identified in Jordan, April 2012 (Al-Abdallat et al., 2014).
matter of time that SARS CoV2 might infect camels as well. This is especially concerning for countries such as Saudi Arabia and in the UAE with over 700,000 and 850,000 reported cases of SARS CoV2 respectively, two countries that have large MERS CoV-infected camel populations.

With this in mind, here we describe the functional reconstitution of the MERS CoV Receptor Binding Motif (RBM) which is the main neutralizing epitope for beta-coronaviruses and thus could provide an effective immunoegen for the development of a MERS CoV epitope-based vaccine, to be considered for humans and camels alike.

2. Materials and methods

2.1. Vectors

The fth1 vector was developed at Tel Aviv University as previously described (Enshel-Sejifiers et al., 2001) and subsequently modified for expression of recombinant peptides as fusions at the N-terminus of the infectivity protein, P3, of fd filamentous bacteriophage (Smelyanski and Gershoni, 2011). The pMALc vector system was provided by N. T. Freund, Tel Aviv University. The pET30a-N6xHisGST vector was used to express recombinant peptides as fusions at the N-terminus of the protein.

2.2. Antibodies and Receptor

Seven neutralizing mAbs that target the MERS CoV RBM were used in this study: human mAbs m-336, m-337, m-338 were kindly provided by L. Uppalapati et al., 2015. Recombinant human CD26 protein (Fc-chimera) was purchased from Abcam (ab 155730), Zotal, Israel. Polyclonal rabbit anti-M13 infectivity protein, P3, of fd filamentous bacteriophage (Smelyanski and Gershoni, 2011 and served as the basis for the reconstitution of the MERS CoV Receptor Binding Motif (RBM) which is the main neutralizing epitope for beta-coronaviruses and thus could provide an effective immunoegen for the development of a MERS CoV epitope-based vaccine, to be considered for humans and camels alike.

2.2. Antibodies and Receptor

Seven neutralizing mAbs that target the MERS CoV RBM were used in this study: human mAbs m-336, m-337, m-338 were kindly provided by D. S. Dimitrov and T. Ying. The human mAb CDC-C2, mouse mAbs F-11 and C-12 and rhesus macaque mAb JC57–11 were kindly provided by B. S. Graham (see Lingshu et al., 2021; Wang et al., 2015; Ying et al., 2014). Recombinant human CD26 protein (Fc-chimera) was purchased from Abcam (ab 155730), Zotal, Israel. Polyclonal rabbit anti-M13 serum was produced in the Gershoni Laboratory in-house at Tel Aviv University. HRP-conjugated antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc (West Grove, PA, USA).

2.3. Construction of the MERS CoV RBM conformer library

Reconstitution of the SARS CoV RBM was previously described (Freund et al., 2015) and served as the basis for the reconstitution of the MERS CoV RBM. In principle, segments of the natural MERS CoV RBM were connected via combinatorial linkers thus, yielding a diversity of conformers. In view of the fact that the MERS CoV RBM is larger than that of SARS CoV, the libraries were expressed and displayed on Protein, P3 of the fd filamentous bacteriophage (5 copies per phage). Thus, virus specific combinatorial phage-display conformer libraries were produced. For this, the modified fth1 vector (Smelyanski and Gershoni, 2011), was used for the construction of the MERS CoV RBM conformer libraries.

Specifically, a gBlock of double stranded DNA sequences corresponding to the MERS CoV RBM (K493 – E655, the “full length RBM”) (Raj et al., 2013), containing fth1 BstXI overlapping sequences on both 5’ and 3’ ends was purchased from Integrated DNA Technologies (IDT, Israel). This was then used as a PCR-template to generate two segments corresponding to:

Segment A, amino acid residues K493-P515 of the MERS CoV RBM followed by a series of linkers of 3, 4, 5, 6 and 7 random amino acids in length (using sense Primer #1 paired against antisense Primers #3–7) or no linker at all (antisense Primer #2).

Segment B, residues C526-E565 of the MERS CoV RBM (using the sense Primer #8 and antisense Primer #9) of note, residue cysteine 526 was retained as part of the RBM in order to maintain the disulfide C526-C503 that stabilizes the RBM.

Primers: (note, Primers #3–7 are antisense and thus contain “MNN” antisense codons that complement NKN sense codons):

1. 5’CCTTTCTATTTCTCCTCGCTC 3’
2. 5’GGATGGGACATTGATACACAMNNMNNMNNAGGTACCTCGA CAG 3’
3. 5’GGATGGGACATTGATACACAMNNMNNMNNAGGGTACCT CAG TACGATACAGA 3’
4. 5’GGATGGGACATTGATACACAMNNMNNMNNMNNAGGTTAC TGGTGGATACAGA 3’
5. 5’GGATGGGACATTGATACACAMNNMNNMNNMNNMNNAGG TACGATACAGA 3’
6. 5’GGATGGGACATTGATACACAMNNMNNMNNMNNMNNMNN MNNAGGTTACGATACAGA 3’
7. 5’GGATGGGACATTGATACACAMNNMNNMNNMNNMNNMNN MNNAGGTTACGATACAGA 3’
8. 5’TGGTATGACTATGATACAGA 3’
9. 5’CCTTTCAACAGTCTTCAGAC 3’

All PCR products were purified using AMPure beads (Beckman Coulter, Indianapolis, IN, USA) and cloned into BstXI precut vector by Gibson assembly reactions (Gibson et al., 2010). Thus, the following constructs were generated:

• “Full Length” RBM (FL), residues 493–565 including the “anchor loop” (residues Q516-P525);
• “Loopless” RBM (LL), in which residues P515 and C526 are connected directly to one another, with no amino acids in place of the deleted loop;
• RBM random conformers containing any one of 5 random linkers (3, 4, 5, 6 and 7 amino acids), in place of the deleted “anchor loop”.

Ethanol-purified Gibson reaction products were used to electroporate E. coli ER2738 electro-competent cells (cat. no. 60522–1, Lucigen, Middleton, WI, USA) and clones were isolated and confirmed for correct sequence by standard Sanger’s sequencing. Bacteria were cultured (shaking at 225 rpm, 37 °C, overnight), and phages were precipitated from culture media using polyethylene glycol 6000/NaCl and resuspended in Tris buffered saline (50 mM Tris-HCl pH 7.5, 150 mM NaCl (TBS)).

2.4. Screening of the conformer libraries

The conformer libraries were screened against MERS CoV neutralizing mAbs. The following mAbs were used: human neutralizing mAbs m-336, m-337, m-338 and CDC-C2; macaque mAbs JC57–11; and m urine mAbs F-11 and C-12 (Wang et al., 2018; Xu et al., 2019; Ying et al., 2014; Zhang et al., 2018).

In general, screening was performed as previously described. Briefly, 2 μg of mAb were added to 1011 phages suspended in 3% bovine serum albumin in TBS, in total volume of 100 μl and incubated at room temperature for 1 h on a rotator. 30 μl of magnetic Protein-G beads (Dynabeads™ Protein G, Cat. No. 10009D, Invitrogen by Thermo Fisher Scientific, CA, USA) were added to the mAb-phage suspension and incubated for 30 min on a rotator. Unbound mAb and phages were removed from the beads by three rounds of washing with TBS (0.5% Tween-20 in TBS) using a magnetic stand. The mAb-bound phages were eluted with glycine-HCl pH 2.2 and neutralized with Tris-HCl pH 9.1. The eluted phages were used to infect DH5αF+ cells for amplification as previously described (Freund et al., 2015). Three additional rounds of amplification and screening were carried out for each mAb. In order to confirm mAb binding to affinity-selected phages, single colonies were picked and grown as mini-cultures from which dot-blots on nitrocellulose membrane filters were prepared. The filters were blocked using 5% skim milk in TBS for 1 h at room temperature, probed with mAbs (2 µg/ml) overnight at 4 °C and subsequently detected using HRP-conjugated antibodies (1:5000, Jackson ImmunoResearch Laboratories, Inc, West Grove, PA, USA). Signals were developed using the enhanced chemoluminescence (ECL) reaction (Rhenium, Israel).

L. Uppalapati et al. / Molecular Immunology 145 (2022) 3–16
2.5. Sample preparation for NGS

Phages from the 4th eluate (and the naïve library) were used as templates for PCR using:

1. **sense primer**: containing Illumina “Adapter A” sequence followed by a 5-base barcode (barcode = NNNNN) and then the 4 codons corresponding to residues 512–515 of Segment A, just preceding the linker sequence:

   5’ AATGATACGGCGACACCGAGATCTACACTCTTCTCCATACGAGCGTCTCGATCTNNNNNACTGAAGTACCT 3’

2. **antisense primer**: containing Illumina “Adapter B” sequence followed by the codons corresponding to residues 525–528 in Segment B:

   5’ CAGACGAAAGACGGCTACAGCTCTCTCCATCTAATGGGATCACA 3’

The thermal profile was:

1. 94 °C 5 min
2. 94 °C 1 min
3. 53 °C 1 min
4. 72 °C 20 s
5. steps 2–4 × 35 cycles
6. 72 °C 5 min

The amplified PCR products were validated for size in a 2% agarose gel. PCR samples were purified on AMPure beads (Beckman Coulter, Indianapolis, IN, USA) diluted to give 10 nM, pooled into a single tube and sent for NGS (Illumina HiSeq High Output, SR60-V4).

2.6. Peptide linker Motif Analysis

We used the multiple peptide linkers as input for the Motif Elicitation (MEME, “zoop mode”) algorithm (Bailey and Elkan, 1994) for linker motif discovery.

2.7. Construction of reconstituted MERS CoV RBMs as MBP/GST conjugates

The reconstituted MERS CoV RBMs were amplified by PCR from fth1 constructs using the sense primer #10 and antisense primer #11 containing overlapping sequences for Ndel, HindIII for maltose binding protein (MBP), and the sense primer #12 and antisense primer #13 containing overlapping sequences for BamHI and HindIII for glutathione-S-transferase (GST).

**Primer**s **#10–13**:

10: 5’TTCAGGGCATTTCTACATAAGGCTCTTCTAAATGACAGCT 3’
11: 5’AGGCCTTTGTTTTATTTAGCTTTTACTCAGTCTAGGGCAACAGCT 3’
12: 5’GATCTGTTTCCGCTGATCCAAAAAGCTTTCTAAGATCGAT 3’
13: 5’GAGTGCCGGCGGCGTAAGCTCTTCATCAGTGCAATGGCAACAGCT 3’

The thermal profile was:

1. 94 °C 5 min
2. 94 °C 30 s
3. 50 °C 30 s
4. 72 °C 30 s
5. steps 2–4 × 35 cycles
6. 72 °C 5 min

The amplified PCR products were validated for size in a 2% agarose gel. All PCR products were purified using AMPure beads and cloned into Ndel/HindIII precut pMAL-p5x-MBP vector for MBP constructs and BamHI/HindIII precut pET30a-N6xHis-GST vector for GST constructs using Gibson assembly reaction.

For both expression systems, the vectors were transformed into E. coli BL21 Rosetta (DE3) bacteria (Novagen Merck, Darmstadt, Germany) and used to produce MBP and GST constructs using 100 mM IPTG for 5 h induction at 37 °C.

2.8. Protein production and purification

E. coli BL21 Rosetta (DE3) cells were transformed with recombinant plasmids coding for MERS CoV RBMs conjugated with either MBP or GST. The transformed cells were grown in 200 ml LB medium + 100 µg/ml ampicillin (for pMAL-p5x-MBP) or 50 µg/ml kanamycin (for pET30a-N6xHis-GST) at 37 °C. When the culture reached OD_{600} nm = 0.6, 1 ml of 100 mM isopropyl β-d-1-thiogalactopyranoside (IPTG, Bio-Lab, 162423) was added and incubated for additional 5 h at 37 °C.

The saturated bacterial cultures were harvested by centrifugation at 5000 rpm for 10 min. The bacterial pellet was resuspended in Lysis buffer (PBS containing 0.1% Triton X-100, 0.2 M NaCl) and lysed by sonication. The lysates were clarified by centrifugation at 14,000 rpm for 30 min, the supernantant was discarded. The pellet inclusion bodies were resuspended by sonication in 40 ml lysis buffer containing 8 M urea (ice cold), then incubated with 200 µl of Nickel beads overnight at 4 °C on a rotator to extract protein from inclusion bodies.

The fusion proteins were affinity purified by metal ion affinity chromatography on Sepharose-nickel beads according to the supplier’s instructions (Ni Sepharose 6 Fast Flow, GE Healthcare Life Sciences, 17–5318–06) using gravity columns. The buffer exchange following elution was done using Amicon Ultra-15 centrifugal filter 30k for MBP and 10k for GST fusion proteins (Merck; UFC903024, Ireland). Protein purity was estimated using polyacrylamide gel electrophoresis (12%). The yields ranged from 1 to 7 mg of purified protein per 200 ml of culture.

2.9. Immunizations

Six New Zealand female white rabbits were purchased from Envigo, Tel Aviv, Israel. Rabbits were housed under specific pathogen free conditions. All procedures used in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of Tel Aviv University, Israel.

Two rabbits (body weight 1.4 – 1.8 kg) per each antigen: E5 and E9, and two rabbits for control scaffolds (MBP and GST) were immunized with 0.5 mg/ml of each E5-MBP, E9-MBP and MBP scaffold emulsified with complete Freund’s Adjuvant via subcutaneous injections at 5 different sites. Subsequently, three booster doses of antigens using alternate scaffolds of MBP or GST were administered with incomplete Freund’s Adjuvant at 18 days of dose intervals. Pre-immune and immune blood samples (5mls) were collected from the marginal ear-vein of each animal a day before each immunization or boost.

2.10. Enzyme-linked immunosorbent assay (ELISA)

ELISA tests were conducted to evaluate antibody binding to the various RBM constructs and for the measure of the antibody response in immunized animals.

2.10.1. RBM capture assays

ELISA plate wells were coated overnight with 5 µg/ml of the different neutralizing mAbs in TBS. Next, the plates were washed with TBS, blocked with 5% skim milk in TBS and incubated with phages displaying the RBM constructs (10^10 phages/well). Wells were washed with TBS (0.05% Tween-20) and incubated with polyclonal rabbit anti-M13 serum (1:10,000). Next, wells were washed and incubated with HRP-conjugated goat anti-rabbit antibody (1:5000, Jackson ImmunoResearch Laboratories, Inc, West Grove, PA, USA). Following an additional round of washing, wells were reacted with the TMB/E ELISA substrate (Merck Millipore; ES001, USA). Absorbance was measured at
650 nm using a micro-plate reader (Bio Tek, Winooski, VT, USA). All samples were tested in duplicate and experiments were repeated at least three times.

2.10.2. Measure of antibody binding to MBP and GST constructs

The MBP and GST fusion proteins displaying the RBM constructs were used to coat wells overnight (10 µg/ml in TBS), washed with TBS, blocked with 5% skim milk in TBS and incubated with 2 µg/ml neutralizing mAbs, overnight at 4 °C. The secondary antibodies (HRP conjugates) corresponding to each of the neutralizing antibodies were added 1:5000 in skim milk and incubated for 45 min at room temperature (Jackson ImmunoResearch Laboratories, Inc, West Grove, PA, USA). Following an additional round of washing, wells were reacted with the TMB/E ELISA substrate (Merck Millipore; ES001, USA). Absorbance was measured at 650 nm using a micro-plate reader (Bio Tek, Winooski, VT, USA). All samples were tested in duplicate and experiments were repeated at least three times.

2.10.3. ELISA tests of rabbit sera

The sera samples were analyzed first against phage displayed immunogens (E5, E9) and control phage (fth1) directly used to coat the ELISA wells and followed the general protocol above probing with

![Fig. 1. Receptor Binding Domains (RBDs) of SARS CoV and MERS CoV. Backbone representations of the RBDs of SARS CoV (A, PDBID:2GHV) and MERS CoV (B, PDBID:4KQZ) are shown. Both structures contain a central core harboring 5 beta-strands. An excursion leaves the core (pink), from beta-strand 4, forming an extended surface that contacts the virus receptor and is the target of neutralizing mAbs thus forming the RBM as has been confirmed for SARS CoV (Li et al., 2005) and MERS CoV (Lu et al., 2013). The fifth core beta strand (purple), serves as a lynch-pin that stabilizes the structure. The RBM excursion is held in place via an “anchor loop” (a.l., blue) that forms hydrogen bonds with the RBD core. In C more detailed comparison of the two RBMs is given. Here the markedly more complex MERS CoV RBM is illustrated showing an additional beta strand (purple) complicates the folding and conformation compared to the simple RBM of SARS CoV that contains only two beta strands (red and orange) also shared in the RBM of MERS CoV. Note also the position of the C503-CS26 disulphide at the rim of the anchor loop of the MERS CoV RBM.](image-url)
serum samples diluted 1:10,000 in milk. Subsequently, the reaction against recombinant MERS CoV spike S1 protein antigen was tested, using the commercial anti-MERS CoV ELISA (IgG) kit, (EI 2604–9601 G, EUROIMMUN Medizinische Labordiagnostika AG, Lübeck). Wells were washed with TBST and incubated with the polyclonal rabbit pre-immune or immune sera (as per kit instructions) followed by washes and incubation with secondary antibody HRP-conjugate as described above.

3. Results and Discussion

The 2002 SARS CoV Receptor Binding Domain (RBD, 193 amino acids) was functionally identified two years after the death of Patient Zero (Li et al., 2003). The atomic structure of the RBD was solved by X-ray diffraction analysis of its co-crystal with the corresponding viral receptor, angiotensin converting enzyme 2 (ACE2) (Li et al., 2005) and then with the neutralizing mAb 80 R (Sui et al., 2004). These co-crystals revealed a Receptor Binding Motif (RBM, residues S432-T486); an extended excursion that runs along the surface of the central core of the RBD and presents the active surface that directly contacts the receptor as well as the competing neutralizing mAb (Fig. 1A). We were able to reconstitute an isolated RBM of SARS CoV (42 amino acids) that binds both the neutralizing mAb and the receptor (Freund et al., 2015).

With the emergence of MERS CoV in 2012, its RBD was co-crystallized along with its corresponding receptor, human dipeptidyl peptidase 4 (huDPP4) (Lu et al., 2013), revealing a conformational layout which generally follows the structure elucidated previously for SARS CoV. The MERS CoV RBD contains a central core stabilized with 5 beta strands and an excursion, stemming from the fourth beta strand, that runs along the surface of the core and returns, inserting the fifth
beta strand that serves as a lynch-pin stabilizing the compact RBD structure (Fig. 1 B).

Examination of the MERS-CoV RBD co-crystals with its receptor or various neutralizing mAbs (Ying et al., 2014; Zhang et al., 2018) confirms the RBM which, however, is markedly larger and more complex compared to that of SARS CoV. The MERS CoV RBM (residues K493-E565) consists of 73 amino acids and contains an “anchor loop” (from Q516 through P525, shaded light-blue). Six neutralizing mAbs have been co-crystallized with MERS CoV RBD, and their atomic structures have been solved (Lingshu et al., 2021; Xu et al., 2019; Ying et al., 2015; Zhang et al., 2018). As is illustrated, each mAb uses an array of contacts to bind the virus RBM, none of which are in the “anchor loop”. For comparison, the contacts with the MERS CoV receptor, huDPP4, are given. Note that three huDPP4 contact residues (R505, P515 – green asterisks, and A562 – red asterisk) do not directly contribute to mAb recognition.

3.1. Construction of the conformer combinatorial linker library

The RBM oligonucleotide sequence (corresponding to residues K493-
Table 2
NGS analysis of 25 RBM clones. The MERS CoV conformer library was screened with 7 mAbs and the affinity-selected phages were sent to NGS analysis. The sequences for the various linkers used to replace the “anchor loop” were determined and are ranked for the SUM of reads scored for all seven mAbs. Also shown is the number of mAbs (#mAbs) for which reads were detected. Linkers for which a “Name” is provided (highlighted rows) are those that were also manually picked and confirmed as binders as is illustrated (see text). Note, the 5 linkers that were further characterized in Fig. 7 are given in bold.

| #  | Name  | Linkers | m-336 | m-337 | m-338 | C-12 | F-11 | JC57-11 | CDC-C2 | mAbs | SUM  |
|----|-------|---------|-------|-------|-------|------|------|---------|--------|------|------|
| 1  | D8    | LALSA   | 828,420 | 936,441 | 705,321 | 236,722 | 787,062 | 881,111 | 875,784 | 7    | 5250,861 |
| 2  | A11   | QPPTE   | 6421   | 8833   | 15,310 | 35,710 | 93,455  | 33,310  | 25,934 | 7    | 218,973 |
| 3  | E5    | LHPDHPD | 19,234 | 12,271 | 33,687 | 2428   | 5061    | 20,025  | 10,440 | 7    | 103,146 |
| 4  | LRT   |         | 22,934 | 889    | 4707   | 48,882 | 8058    | 1730    | 15,589 | 7    | 102,789 |
| 5  | NRG   |         | 13,415 | –      | 4600   | 34,760 | 36      | 1111    | 900    | 6    | 54,822  |
| 6  | BC10  | MAPQT   | 2619   | 547    | 2729   | 30,823 | 3827    | 1958    | 2090   | 7    | 44,393  |
| 7  | G3    | LSKEY   | 3327   | 213    | 13,942 | 1656   | 1266    | 2051    | 184    | 7    | 22,639  |
| 8  | BA5   | LPRKE   | 10,266 | 1330   | 1758   | 4470   | 35      | 1     | 3165   | 7    | 20,995  |
| 9  | ED2   | YDLFVKE | 2331   | 96     | 335    | 162    | 4659    | 177     | 7      | 20,934 |
| 10 | BB2   | LNHAE   | 2690   | 94     | 12,733 | 3293   | 42      | 108     | 224    | 7    | 19,184  |
| 11 | LSRDS |         | 1061   | 185    | 12,009 | 3387   | –       | 967     | 0      | 5    | 17,609  |
| 12 | LEMIE |         | 1247   | –      | 8402   | 1960   | 230     | 2311    | 1      | 6    | 14,151  |
| 13 | MNRSDA|         | 461    | –      | 12,068 | –      | –       | 1       | 0      | 3    | 12,530  |
| 14 | EC2   | LPFEE   | 380    | 305    | 4862   | 278    | 4668    | 1224    | 728    | 7    | 12,445  |
| 15 | AA5   | VPVHR   | 2074   | 484    | 4387   | 101    | 4926    | 125     | 170    | 7    | 12,267  |
| 16 | LSAHSP |         | 183    | –      | 11,781 | –      | –       | –       | 90     | 3    | 12,054  |
| 17 | SNQ   |         | –      | 90     | 238    | –      | –       | –       | 10,648 | 941  | 4      | 11,917 |
| 18 | BC3   | LPRHIN  | 3290   | 1588   | 2979   | 63     | –       | 1916    | 540    | 6    | 10,376  |
| 19 | EC6   | YSVPSVT | 616    | –      | 417    | 5113   | 2712    | –       | 213    | 5    | 9071    |
| 20 | ETIPSYN|         | 3999   | 163    | 366    | 1457   | 19      | 235     | 2512   | 7    | 8751    |
| 21 | MFPTDPK|         | 129    | –      | 7882   | –      | –       | –       | 0      | 2    | 8011    |
| 22 | BB6   | LSPTE   | 2503   | 202    | 3360   | –      | 385     | 2       | 840    | 6    | 7292    |
| 23 | BA3   | LSNEA   | 1412   | 4      | 4463   | 2      | –       | 574     | 0      | 5    | 6455    |
| 24 | LSATNSA|         | 53     | –      | 6118   | –      | –       | –       | 0      | 2    | 6171    |
| 25 | E9    | LPLQA   | 133    | 267    | 321    | 14     | 36      | 302     | 2      | 7    | 1075    |

Fig. 5. Assignment of MEME motifs to cross reactive linkers. Over 1000 clones from the screening of the conformer library were manually picked and tested for each of the 7 neutralizing mAbs used in this study. The following linkers supported binding of at least two different mAbs: LALSA, QPPTE, LSKEY, LPLQA, and LHPDHPD. Furthermore, affinity-selected peptides from these screens were sent to NGS analysis. 1415 pentameric linkers and 242 heptameric linkers were found to have more than 1000 copies and to cross-react with at least two mAbs. Using the MEME algorithm (REF), 17, 15, 10, 28 and 33 linkers could be assigned to the LALSA, QPPTE, LSKEY, LPLQA, and LHPDHPD linkers, respectively. The motifs defined by MEME using the 1657 peptides (pentamers + heptamers) correspond well with the 5 linkers obtained manually.
Combinatorial linkers ranging from 3 to 7 amino acids in length (see E565, 73 amino acids) was cloned into the phage m336 mAb is given as a positive control (**). The fth1 wild type phage (*) shows the level of background binding while a fourth wild type phage provides a negative control (***).

For each of the different mAbs, 1000 phage-displayed conformer clones were initially screened against the MERS CoV receptor protein, huDPP4, but without success, no constructs were able to make a majority of contacts only downstream to the “anchor loop”. Hence, each mAb presents a different set of conformational requirements for RBM binding (further illustrated in Fig. 4B). Consequently, a construct that cross-reacts with multiple mAbs should be viewed as satisfying a broad set of conformational constraints that are important for antibody recognition. Each of the 7 mAbs was used to screen the conformer library in triplicate and the enriched phages were sent to NGS. As is illustrated in Table 2, numerous linkers were found for RBM constructs that were affinity enriched by all 7 mAbs. Although some short, 3 amino acid and 4 amino acid linkers were selected; the majority of effective linkers were 5 and 7 residues long. Considering variations in linker compositions one can easily assign many of the linkers to the 5 motifs shown in Fig. 5. Note that a Leucine residue in the third position, Proline is prevalent in positions two and three.

In order to confirm that the enriched linker-sequences actually produce functional reconstituted RBMs that physically bind the mAbs, we manually screened the library against the mAbs, picking over 1000 clones for each and testing mAb binding by dot blot overlay as is illustrated in Fig. 6. The linkers of the positive clones were determined and found to correspond to the most enriched linkers seen previously in silico by the NGS analyses, thus confirming their ability to actually support conformations recognized by the panel of neutralizing antibodies (see Table 2). Fig. 7 shows the binding of five selected clones to all 7 mAbs.
Two clones in particular, clones E5 and E9, were found to be broadly cross-reactive. These two conformers were then expressed as fusion proteins of maltose binding protein (MBP) and glutathione-S-transferase (GST), thus testing their binding capacity as monovalent epitopes as compared to their polyvalent presentations (5 Protein-3 copies per phage) in the context of the phages. Fig. 8 depicts the binding of the four constructs against all 7 mAbs. Generally, the MBP construct of the E9 conformer showed the highest cross reactive mAb binding. GST also supported functional representation of the two conformers.

3.3. Testing the immunogenicity of the constructs

The next question we addressed is whether or not the MBP or GST E5 and E9 constructs were immunogenic. For this, rabbits were immunized with E5-MBP or E9-MBP and then followed with boosts alternating between MBP or GST constructs. Control rabbits were immunized and boosted with the MBP/GST scaffolds alone. Pre-immune and final immune sera were collected and tested for their ability to specifically bind the E5 and E9 constructs expressed on phages. As is illustrated in Fig. 9, the E5 and E9 immunized rabbits mounted strong antibody responses to the reconstituted RBMs as compared to negligible background by sera of the control animals. We then tested whether or not the RBM specific antibodies cross-reacted with genuine MERS CoV spike protein. For this the sera were tested using the commercial Euroimmun Anti-MERS CoV ELISA (IgG) kit in which recombinant MERS CoV spike protein is provided as the reference antigen. As is demonstrated in Fig. 8.

Two clones in particular, clones E5 and E9, were found to be broadly cross-reactive. These two conformers were then expressed as fusion proteins of maltose binding protein (MBP) and glutathione-S-transferase (GST), thus testing their binding capacity as monovalent epitopes as compared to their polyvalent presentations (5 Protein-3 copies per phage) in the context of the phages. Fig. 8 depicts the binding of the four constructs against all 7 mAbs. Generally, the MBP construct of the E9 conformer showed the highest cross reactive mAb binding. GST also supported functional representation of the two conformers.

3.3. Testing the immunogenicity of the constructs

The next question we addressed is whether or not the MBP or GST E5 and E9 constructs were immunogenic. For this, rabbits were immunized with E5-MBP or E9-MBP and then followed with boosts alternating between MBP or GST constructs. Control rabbits were immunized and boosted with the MBP/GST scaffolds alone. Pre-immune and final immune sera were collected and tested for their ability to specifically bind the E5 and E9 constructs expressed on phages. As is illustrated in Fig. 9, the E5 and E9 immunized rabbits mounted strong antibody responses to the reconstituted RBMs as compared to negligible background by sera of the control animals. We then tested whether or not the RBM specific antibodies cross-reacted with genuine MERS CoV spike protein. For this the sera were tested using the commercial Euroimmun Anti-MERS CoV ELISA (IgG) kit in which recombinant MERS CoV spike protein is provided as the reference antigen. As is demonstrated in Fig. 8.
Reconstitution required the replacement of the MERS CoV RBM, which was the basis for this study. The annual cases of MERS CoV combined with an ever-increasing rise in SARS CoV2 infections in the Middle East, taken together with the high prevalence of MERS CoV in camel populations, could lead to genetic recombination of these two beta-coronaviruses. The consequence of such an event would be devastating. Hence, we believe that the pursuit of the MERS CoV RBM-based immunogen described in this study, could provide a preemptive answer should such a development occur.

4. Conclusion

The need to produce a vaccine modality for MERS CoV is relevant in view of the extremely high fatality rate for MERS CoV disease. The very low global prevalence of MERS CoV is not a reason to dismiss this concern. The annual cases of MERS CoV combined with an ever-increasing rise in SARS CoV2 infections in the Middle East, taken together with the high prevalence of MERS CoV in camel populations, could lead to genetic recombination of these two beta-coronaviruses. The consequence of such an event would be devastating. Hence, we believe that the pursuit of the MERS CoV RBM-based immunogen described in this study, could provide a preemptive answer should such a development occur.

Funding

This work was supported by grants from the Israel Science Foundation (grant no. 437/16, J.M.G.), The USA-Israel Binational Science Foundation (grant no. 2005290, J.M.G. and Dr. Wayne Marasco) and the Recanati Foundation (grant no. 960220, J.M.G.) as well as generous donations from the Frankel Foundation, Peter Kraus and the Jakov, Miriana and Jorge Saia Fellowship (J.M.G.). This work was supported in part by intramural funding from the National Institute of Allergy and Infectious Diseases (B.S.G.).

CRediT authorship contribution statement

J.M.G. developed the concept and design of Coronavirus RBM reconstitution and L.U. designed and executed the MERS CoV RBM reconstitution experiments, D.S.D. and T.Y. provided neutralizing MERS CoV mAbs and discussion of the RBM reconstitution for MERS CoV, A.R-B. and Y.W-O. assisted throughout the project and the writing of the manuscript. All authors commented on the manuscript at all stages.

Data and materials availability

All data is available in the manuscript.

Acknowledgements

We thank E. Bacharach for critical feedback on the manuscript. We appreciate and recognize N.T. Freund for her work on the initial RBM reconstitution experiments, D.S.D. and T.Y. provided neutralizing MERS CoV mAbs and discussion of the RBM reconstitution for MERS CoV, A.R-B. and Y.W-O. assisted throughout the project and the writing of the manuscript. All authors commented on the manuscript at all stages.

Competing interests

There are no conflicting interests for any of the Authors.

References

Ababneh, M.M., Lafi, S.Q., Abutarbush, S.M., Khalifeh, M.S., Hijazeen, Z.S.K., Ramadneh, W.A., Al Amee, M.S., Abukhalifeh, F.Y., Kutkut, T.A., Dodeen, R.A., El Masry, L., von Dobschuetz, S., 2021. Longitudinal and abattoir-based surveillance of MERS-CoV in camels in Jordan, 2018-2020. e08166-e08166 Heliyon 7. https://doi.org/10.1016/j.heliyon.2021.e08166.

Ab-Abdallat, M.M., Payne, D.C., Aqlasrawi, S., Rha, B., Tohme, R.A., Abedi, G.R., Al Nour, M., Ililan, I., Jarour, N., Farag, N.H., Haddadin, A., Al-Sanouri, T., Tamin, A., Harcourt, J.J., Kubar, D.T., Swerdlow, D.L., Erdman, D.D., Pallansch, M.A., Haynes, L.M., Gerber, S.L., Team, J.M.-C.I., 2014. Hospital-associated outbreak of MERS-CoV in camels in Jordan, 2018-2020. e08166-e08166 Heliyon 7. https://doi.org/10.1016/j.heliyon.2021.e08166.

Ababneh, M., Lafi, S., Abutarbush, S., Khalifeh, M., Hijazeen, Z., Ramadneh, W., Al Ameer, M., Abukhalifeh, F., Kutkut, T., Dodeen, R., El Masry, L., von Dobschuetz, S., 2021. Longitudinal and abattoir-based surveillance of MERS-CoV in camels in Jordan, 2018-2020. e08166-e08166 Heliyon 7. https://doi.org/10.1016/j.heliyon.2021.e08166.

Al-Abdallat, M.M., Payne, D.C., Aqlasrawi, S., Rha, B., Tohme, R.A., Abedi, G.R., Al Nour, M., Ililan, I., Jarour, N., Farag, N.H., Haddadin, A., Al-Sanouri, T., Tamin, A., Harcourt, J.J., Kubar, D.T., Swerdlow, D.L., Erdman, D.D., Pallansch, M.A., Haynes, L.M., Gerber, S.L., Team, J.M.-C.I., 2014. Hospital-associated outbreak of MERS-CoV in camels in Jordan, 2018-2020. e08166-e08166 Heliyon 7. https://doi.org/10.1016/j.heliyon.2021.e08166.
Baddal, B., Caikir, N., 2020. Co-infection of MERS-CoV and SARS-CoV-2 in the same host: A silent threat. J. Infect. Public Health 13, 1251–1252. https://doi.org/10.1016/j.jiph.2020.04.005.

Bailey, T., Elkan, C., 1994. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc. Int. Conf. Intel. Syst. Mol. Biol. 2, 38–36.

Banerjee, A., Mosmann, K., Baker, M.L., 2021. Zoonootic potential of SARS-CoV-2 and its implications into human populations. Cell Host Microbe 29, 160–164. https://doi.org/10.1016/j.chom.2021.01.004.

Berruga-Terán, T., Robesyn, E., Korhonen, T., Penttinen, P., Janna, J.M., 2021. Risk assessment for the transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) on aircraft: a systematic review (https://doi.org/10.1126/sciadv.2000439). Epidemiol. Infect. 149, e142. https://doi.org/10.1017/S095026882100113X.

Chan, J.F.W., Yuan, S., Kok, K.-H., To, K.K.W., Chu, H., Yang, J., Xing, F., Lin, J., Yip, C.C., Tsang, W.-K., Lau, S.K.M., et al., 2020. Lancet. 5, S15. https://doi.org/10.1016/S0140-6736(20)30210-7.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Mediavilla, J.R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.

Chen, L., Zody, M.C., Di Germanio, C., Martinelli, R., Cunningham, M. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., Peiris, J.S.M., Dimonaco, N.J., Salavati, M., Shih, B.B., 2020. Computational Analysis of SARS-CoV-2. FAO. 2021, 2021. Investigating potential recombination of MERS-CoV and SARS-CoV-2 viruses. Transbound. Emerg. Dis. 68, 1850–1867. https://doi.org/10.1111/tbed.13885.
Robert Carlson, M. 2021. COVID-19 and MERS Coinfections Confirmed in Saudi Arabia. Coronavirus today.

Rota, G.C., Oberte, M., Moro, S.S., Nix, W.A., Campagnoli, R., Icognese, J.P., Periandara, S., Bankamp, B., Maher, K., Chen, M.-H., Tong, S., Tamin, A., Lowe, L., Face, M., DeRisi, J.L., Chen, Q., Wang, D., Erdman, D.D., Perrot, T.C.T., Burns, C., Kuzak, T.G., Rollin, P.E., Sanchez, A., Lifshitz, S., Holloway, B., Limor, J., McCaigland, K., Oshawa, S., Fouchet, R., Giannetti, S., Osterhaus, A., Stenfert, E.D., Drosten, C., Pallanch, M.A., Anderson, L.J., Bellini, W.J., 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1318–1320. https://doi.org/10.1126/science.1086924.

Safari, I., Ebi, E. 2021. Evolution of the SARS-CoV-2 genome and emergence of variants of concern. Arch. Virol. 1–13. https://doi.org/10.1007/s00705-021-05295-5.

Sailer, M.Z., Derrick, J.P., Deris, Z.Z. 2021. Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evation. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22147425.

Saylor, K., Gillam, F., Lohneis, T., Zhang, C., 2020. Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy. Front. Immunol. 11, 283.

Schlottau, K., Rissmann, M., Graaf, A., Schor, S., Barton, E., Padgett, D., Scott, G., Swindells, E., Greenaway, J., Nelson, A., Arledge, K.C., Chen, Y.-H., Zhang, L., Wang, X., 2013. Structure of MERS-CoV spike glycoprotein to avoid neutralization escape. J. Virol. 92 https://doi.org/10.1128/JVI.00912-14.

Seo, D., Park, S., Jo, H., Han, J., Shin, J.-H., Kim, J., Park, H., Park, H., Park, G., Kwon, H., 2021. Evaluation of SARS-CoV-2 vaccine candidates in ferrets. Vaccine 43, 362–369. https://doi.org/10.1016/j.vaccine.2021.04.075.

Shi, W., Wang, L., Xing, Z., Li, X., Song, L., Liu, J., Liu, P., Cui, P., Wang, J., Zhang, X., Guan, Y., Tan, W., et al., 2020. Susceptibility of ferrets, cats, dogs, and other hosts to the SARS-CoV-2. Science 368, eaay5051. https://doi.org/10.1126/science.aay5051.

Slocombe, E., Drosten, C., Pallansch, M.A., Anderson, L.J., Bellini, W.J., 2003. Characterization of MERS-CoV in human respiratory specimens. J. Virol. 77, 12120–12127. https://doi.org/10.1128/JVI.77.23.12120-12127.2003.

Tallarico, A.S.C., Olurinde, M., Choe, H., Anderson, L.J., Bellini, W.J., Farzan, M., Dimitrov, D.S., Zhou, T., 2015. Junctional and allele-specific residues are critical for MERS-CoV binding and entry. Virology 488, 1–11. https://doi.org/10.1016/j.virol.2015.06.008.

Vallée, A., Pu, J., Nguyen, T., D’Ogey, S., Martin, T., Agopian, V., et al., 2014. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796–7808. https://doi.org/10.1128/JVI.02002-17.

Walsh, L.F., Shi, Z., Zhang, S., Field, H., Dacozz, P., Eaton, B.T., 2006. Review of bats and SARS. Emerg. Infect. Dis. 12, 1834–1840. https://doi.org/10.3201/02120603.

Wang, L., Shi, W., Chappell, J.D., Joyce, M.G., Zhang, Y., Kaneiko, M., Becker, M.M., van Doremalen, N., Fischer, R., Wang, N., Corbett, K.S., Mason, R.D., Van Boeckel, P.T., Zhou, T., 2015. Close relatives of MERS-CoV in bats use ACE2 as their functional receptor. Nature 519, 607–610. https://doi.org/10.1038/nature14163.

Wang, Y., Zheng, B.-J., Yuen, K.-Y., Jiang, S., Dimitrov, D.S., 2014. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796–7808. https://doi.org/10.1128/JVI.02002-17.

Wu, G., Chen, H., Bu, Z., 2020. Susceptibility of ferrets, cats, dogs, and other animals to SARS-CoV-2. Science 368, 1068–1070. https://doi.org/10.1126/science.abc4644.

Ye, D., Fan, X., Song, J., Sun, Y., Huang, J., Li, S., Yin, S., Wang, S., Chen, H., 2020. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: An experimental transmission study. Lancet Microbe 1, e218–e224. https://doi.org/10.1016/S2258-2229(20)30038-3.

Young, T., Prabakaran, P., Du, L., Shi, W., Feng, Y., Wang, Y., Wang, L., Li, W., Jiang, S., et al., 2021. Enhanced transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. consortium, T.C.-19 G.U., 2021. Middle East respiratory syndrome coronavirus (MERS-CoV) - WHO. 2021. Middle East respiratory syndrome coronavirus (MERS-CoV) - WHO. https://www.who.org/zh/emergencies/disease-outbreak-news/item/2021-DON333. Xiong, Q., Zhao, L., Ma, C., Liu, C., Li, J., Liu, P., Gu, M., Wang, C., Shi, I., Tong, F., Huang, M., Li, J., Zhao, C., Shen, C., Chen, Y., Zhao, H., Lan, K., Wang, X., Yang, H., 2022. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. bioRxiv 2022.01.24.477940. https://doi.org/10.1101/2022.01.24.477940.

Ying, T., Lu, W., Wang, P., Zhang, X., Xin, Y., Yu, Y., Li, H., Li, S., et al., 2014. Experimental potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796–7805. https://doi.org/10.1128/JVI.00912-14.

Ying, T., Prabakaran, P., Lu, D., Shi, W., Feng, Y., Wang, Y., Li, W., Jiang, S., Dimitrov, D.S., Zhou, T., 2015. Functional and allele-specific residues are critical for
MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun. 6, 8223. https://doi.org/10.1038/ncomms9223.

Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D.M.E., Fouchier, R.A.M., 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814–1820. https://doi.org/10.1056/NEJMoa1211721.

Zhang, A.-R., Shi, W.-Q., Liu, K., Li, X.-L., Liu, M.-J., Zhang, W.-H., Zhao, G.-P., Chen, J.-J., Zhang, X.-A., Miao, D., Ma, W., Liu, W., Yang, Y., Fang, L.-Q., 2021. Epidemiology and evolution of Middle East respiratory syndrome coronavirus, 2012–2020. Infect. Dis. Poverty 10, 66. https://doi.org/10.1186/s40249-021-00853-0.

Zhang, S., Zhou, P., Wang, P., Li, Y., Jiang, L., Jia, W., Wang, H., Fan, A., Wang, D., Shi, X., Fang, X., Hammel, M., Wang, S., Wang, X., Zhang, L., 2018. Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep. 24, 441–452. https://doi.org/10.1016/j.celrep.2018.06.041.